Around the Practice: IDH-Mutant Gliomas Treatment Update

Jan Drappatz MD; Elizabeth Maher, MD, PhD; Alexandra M. Miller, MD, PhD; and David Reardon, MD discuss how the 2021 WHO classification emphasizing molecular markers like IDH mutations has transformed glioma treatment from a histology-based approach to personalized therapy, with IDH inhibitors offering new first-line options that can defer radiation and chemotherapy while maintaining quality of life for patients with IDH-mutant gliomas.